Last reviewed · How we verify
Propranolol - Spironolactone
This combination uses propranolol (a beta-blocker) to reduce heart rate and blood pressure, and spironolactone (an aldosterone antagonist) to promote sodium and water excretion while retaining potassium.
This combination uses propranolol (a beta-blocker) to reduce heart rate and blood pressure, and spironolactone (an aldosterone antagonist) to promote sodium and water excretion while retaining potassium. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction management.
At a glance
| Generic name | Propranolol - Spironolactone |
|---|---|
| Sponsor | University Hospital, Angers |
| Drug class | Beta-blocker and mineralocorticoid receptor antagonist combination |
| Target | Beta-adrenergic receptors (propranolol); mineralocorticoid receptor (spironolactone) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Propranolol blocks beta-adrenergic receptors, decreasing cardiac output and renin release, thereby lowering blood pressure and heart rate. Spironolactone antagonizes aldosterone at mineralocorticoid receptors in the collecting duct, promoting sodium and water excretion while conserving potassium. Together, they provide complementary cardiovascular and diuretic effects with potassium-sparing properties.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Post-myocardial infarction management
Common side effects
- Fatigue
- Dizziness
- Hyperkalemia
- Bradycardia
- Sexual dysfunction
- Gynecomastia
Key clinical trials
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Hemodynamic Effects of Chronic Administration of Spironolactone and/or Propranolol in Alcoholic Cirrhotic Patients (PHASE4)
- Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis (PHASE4)
- Liver Transplantation Versus Alternative Therapies for Patients With Pugh B Alcoholic Cirrhosis (NA)
- Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Propranolol - Spironolactone CI brief — competitive landscape report
- Propranolol - Spironolactone updates RSS · CI watch RSS
- University Hospital, Angers portfolio CI